What We Can Learn about Addiction
London, Robert T., Clinical Psychiatry News
Recently I attended a continuing medical education program at Columbia University's College of Physicians and Surgeons.
The program focused on the use of the partial opioid agonist buprenorphine for treating opioid dependence in an office practice. Our focus was on a formulation called Suboxone, which combines buprenorphine and naloxone. Suboxone is the preferred formulation of buprenorphine for maintenance treatment.
My special interest in the treatment of addiction has focused on tobacco smoking, which I believe is our greatest health hazard ("A Twist on Dual Diagnosis," CLINICAL PSYCHIATRY NEWS, January 2005, p. 30). So I was fascinated to learn about some of the progress we have made in treating opioid dependence.
The use of medication for addiction treatment is not new. For example, disulfiram (Antabuse), bupropion (Wellbutrin, Zyban), nicotine patches, and nicotine gum all have their place in addiction medicine. …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: What We Can Learn about Addiction.
Contributors: London, Robert T. - Author.
Magazine title: Clinical Psychiatry News.
Volume: 33.
Issue: 5
Publication date: May 2005.
Page number: 62.
© 2009 International Medical News Group.
COPYRIGHT 2005 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset